Prognostic Factors in a Multicenter Study for Treatment of Acute Lymphoblastic Leukemia in Adults

In a prospective multicenter study. 368 acute lymphoblastic leukemia (ALL) patients aged 1 5 to 65 years were treated with an intensified induction and reinduction regimen; 272 (73.9%) achieved complete remission (CR). The median remission duration (MRD) is 24.3 months, and the probability of being in continuous CR (CCR) at >5 years is .37. The median survival for all 368 patients is 27.5 months, and the probability of being alive at 5 years is .39. For the 272 patients in remission the median survival is 58.4 months, and the probability of being alive at 5 years is .49. A lower CR rate was seen for patients with bleeding at diagnosis or with splenomegaly/hepatosplenomegaly. The prognostic factors unfavorable for remission duration were time to CR >4 weeks v <4 weeks (P = .0002), age >35 years v <35 years (P = .0008), leukocyte count >30,000/